NCT05216965View on ClinicalTrials.gov

A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

208

Participants

Timeline

Start Date

June 11, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Solid Tumors

Interventions

DRUG

9MW2821

All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY